DK2885641T3 - Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension - Google Patents

Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension

Info

Publication number
DK2885641T3
DK2885641T3 DK13830006.6T DK13830006T DK2885641T3 DK 2885641 T3 DK2885641 T3 DK 2885641T3 DK 13830006 T DK13830006 T DK 13830006T DK 2885641 T3 DK2885641 T3 DK 2885641T3
Authority
DK
Denmark
Prior art keywords
risk
predicting
procedures
hypertension
methods
Prior art date
Application number
DK13830006.6T
Other languages
English (en)
Inventor
James V Snider
Original Assignee
Critical Care Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Critical Care Diagnostics Inc filed Critical Critical Care Diagnostics Inc
Application granted granted Critical
Publication of DK2885641T3 publication Critical patent/DK2885641T3/da

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869Interleukin
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52Assays involving cytokines
    • G01N2333/54Interleukins [IL]
    • G01N2333/545IL-1
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/32Cardiovascular disorders
    • G01N2800/321Arterial hypertension
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/50Determining the risk of developing a disease
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
DK13830006.6T 2012-08-16 2013-08-16 Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension DK2885641T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261683956P 2012-08-16 2012-08-16
PCT/US2013/055417 WO2014028875A1 (en) 2012-08-16 2013-08-16 Methods for predicting risk of developing hypertension

Publications (1)

Publication Number Publication Date
DK2885641T3 true DK2885641T3 (da) 2018-01-29

Family

ID=50100476

Family Applications (1)

Application Number Title Priority Date Filing Date
DK13830006.6T DK2885641T3 (da) 2012-08-16 2013-08-16 Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension

Country Status (16)

Country Link
US (3) US9523696B2 (da)
EP (2) EP2885641B1 (da)
JP (3) JP6298466B2 (da)
CN (2) CN104737023B (da)
AU (2) AU2013302451B2 (da)
CA (1) CA2882133A1 (da)
DK (1) DK2885641T3 (da)
ES (1) ES2656897T3 (da)
HK (3) HK1250782A1 (da)
IN (1) IN2015DN01259A (da)
MX (1) MX358541B (da)
NO (1) NO2983845T3 (da)
PL (1) PL2885641T3 (da)
RU (2) RU2683026C2 (da)
SG (2) SG11201501200XA (da)
WO (1) WO2014028875A1 (da)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
EP3072978B1 (en) 2002-05-09 2018-07-11 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
ES2351623T3 (es) 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
DK2827152T3 (da) 2008-04-18 2016-09-12 Critical Care Diagnostics Inc Forudsigelse af risiko for større uønskede hjertehændelser
BR112012025728B1 (pt) 2010-04-09 2022-01-11 Critical Care Diagnostics, Inc Anticorpos isolados ou fragmentos que se liga a st2 humano solúvel, hibridoma, kit, bem como métodos para quantificação de um nível de st2 solúvel humano em uma amostra de um indivíduo, e para a predição do risco de morte dentro de um ano em um indivíduo
EP3605104B1 (en) 2011-03-17 2021-09-15 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
WO2013012945A1 (en) 2011-07-18 2013-01-24 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
CN109212223B (zh) 2012-05-18 2021-11-12 重症监护诊断股份有限公司 用于治疗或预报室性快速性心律失常事件风险的方法
DK2885641T3 (da) 2012-08-16 2018-01-29 Critical Care Diagnostics Inc Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
ES2792227T3 (es) 2014-09-26 2020-11-10 Somalogic Inc Predicción de evento de riesgo cardiovascular y usos de la misma
JP7231326B2 (ja) 2014-11-10 2023-03-01 ジェネンテック, インコーポレイテッド Il-33媒介性障害のための治療及び診断方法
EA201791029A1 (ru) 2014-11-10 2017-12-29 Дженентек, Инк. Антитела против интерлейкина-33 и их применение
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
RU2677611C1 (ru) * 2018-04-16 2019-01-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования неблагоприятных сердечно-сосудистых событий в течение 12 месяцев у больных хронической сердечной недостаточностью с рецидивом стенокардии после реваскуляризации миокарда
US11551817B2 (en) 2020-01-14 2023-01-10 International Business Machines Corporation Assessing unreliability of clinical risk prediction
IL296256A (en) 2020-03-13 2022-11-01 Genentech Inc Antibodies against interleukin-33 and uses thereof
RU2767266C1 (ru) * 2021-05-27 2022-03-17 Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) Способ прогнозирования однолетнего риска неблагоприятных сердечно-сосудистых событий у мужчин после декомпенсации хронической сердечной недостаточности с сохранной фракцией выброса левого желудочка сердца и синдромом обструктивного апноэ во сне

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001070817A1 (fr) * 2000-03-21 2001-09-27 Medical & Biological Laboratories Co., Ltd. Anticorps monoclonal et methode et kit d'immunodosage de st2 humaine soluble l'utilisant
AU2002218026A1 (en) 2000-11-09 2002-05-21 The Brigham And Women's Hospital, Inc. Cardiovascular disease diagnostic and therapeutic targets
US7189518B2 (en) * 2001-11-05 2007-03-13 The Brigham And Women's Hospital, Inc. Soluble CD40L(CD154) as a prognostic marker of atherosclerotic diseases
EP3072978B1 (en) 2002-05-09 2018-07-11 The Brigham and Women's Hospital, Inc. 1l1rl-1 as a cardiovascular disease marker
US20050123451A1 (en) 2003-10-31 2005-06-09 Hiroshi Nomura System and apparatus for body fluid analysis using surface-textured optical materials
AU2005311601B2 (en) * 2004-12-03 2011-12-01 Rhode Island Hospital Diagnosis and treatment of Alzheimer's Disease
ES2351623T3 (es) * 2006-04-24 2011-02-08 Critical Care Diagnostics, Inc. Predicción de la mortalidad y detección de una enfermedad grave.
US20090305265A1 (en) 2006-04-27 2009-12-10 Critical Care Diagnostics, Inc. Interleukin-33 (il-33) for the diagnosis and prognosis of cardiovascular disease
PT2021796E (pt) 2006-05-01 2012-04-19 Critical Care Diagnostics Inc Diagnóstico de doença cardiovascular
HUE025058T2 (en) 2006-05-02 2016-01-28 Critical Care Diagnostics Inc Differential diagnosis of pulmonary and cardiovascular disease
WO2007130627A2 (en) * 2006-05-04 2007-11-15 The Brigham And Women's Hospital, Inc. Il-33 in the treatment and diagnosis of diseases and disorders
GB0703514D0 (en) * 2007-02-23 2007-04-04 Univ Ulster Use of riboflavin
US20080300798A1 (en) * 2007-04-16 2008-12-04 Mcdevitt John T Cardibioindex/cardibioscore and utility of salivary proteome in cardiovascular diagnostics
EP2293076B1 (en) * 2007-08-03 2012-12-19 B.R.A.H.M.S GmbH Use of procalcitonin (PCT) in risk stratification and prognosis of patients with a primary, non-infectious disease
DK2827152T3 (da) 2008-04-18 2016-09-12 Critical Care Diagnostics Inc Forudsigelse af risiko for større uønskede hjertehændelser
JP5711131B2 (ja) * 2008-10-07 2015-04-30 ベー.エル.アー.ハー.エム.エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 最初の有害事象の予測のためのバイオマーカー
CN102472752B (zh) * 2009-08-28 2015-08-19 B.R.A.H.M.S有限公司 用于不良事件的预后的降钙素原
BR112012025728B1 (pt) 2010-04-09 2022-01-11 Critical Care Diagnostics, Inc Anticorpos isolados ou fragmentos que se liga a st2 humano solúvel, hibridoma, kit, bem como métodos para quantificação de um nível de st2 solúvel humano em uma amostra de um indivíduo, e para a predição do risco de morte dentro de um ano em um indivíduo
GB201013151D0 (en) * 2010-08-04 2010-09-22 Isis Innovation Diagnostic method
EP3605104B1 (en) 2011-03-17 2021-09-15 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
WO2013012945A1 (en) 2011-07-18 2013-01-24 Critical Care Diagnostics, Inc. Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
US20130157290A1 (en) * 2011-12-16 2013-06-20 Yves Levy Soluble st2 as a marker for disease
CN109212223B (zh) 2012-05-18 2021-11-12 重症监护诊断股份有限公司 用于治疗或预报室性快速性心律失常事件风险的方法
DK2885641T3 (da) 2012-08-16 2018-01-29 Critical Care Diagnostics Inc Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
CN104737170A (zh) 2012-08-21 2015-06-24 重症监护诊断股份有限公司 多标记风险分层
CA2935958A1 (en) 2014-01-10 2015-07-16 Critical Care Diagnostics, Inc. Methods and systems for determining risk of heart failure
USD770057S1 (en) 2014-04-14 2016-10-25 Critical Care Diagnostics, Inc. Blood test kit
USD800332S1 (en) * 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
USD800333S1 (en) * 2014-09-23 2017-10-17 Critical Care Diagnostics, Inc. Blood test kit
US10079073B2 (en) 2014-12-11 2018-09-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker
US10324089B2 (en) 2014-12-11 2019-06-18 Critical Care Diagnostics, Inc. Test apparatus and methods for ST2 cardiac biomarker

Also Published As

Publication number Publication date
AU2013302451A1 (en) 2015-03-05
US20170219610A1 (en) 2017-08-03
AU2019202597A1 (en) 2019-05-02
IN2015DN01259A (da) 2015-07-03
JP2020196757A (ja) 2020-12-10
SG10201704311VA (en) 2017-07-28
HK1212022A1 (en) 2016-06-03
US20140051773A1 (en) 2014-02-20
EP2885641A1 (en) 2015-06-24
HK1208075A1 (en) 2016-02-19
JP2015526727A (ja) 2015-09-10
AU2013302451B2 (en) 2019-01-17
RU2683026C2 (ru) 2019-03-26
CN107478841A (zh) 2017-12-15
WO2014028875A1 (en) 2014-02-20
CN104737023A (zh) 2015-06-24
US9523696B2 (en) 2016-12-20
JP2018135330A (ja) 2018-08-30
HK1250782A1 (zh) 2019-01-11
JP6298466B2 (ja) 2018-03-20
EP2885641B1 (en) 2017-11-01
RU2015108959A (ru) 2016-10-10
CA2882133A1 (en) 2014-02-20
NO2983845T3 (da) 2017-12-16
RU2019107598A (ru) 2019-03-28
ES2656897T3 (es) 2018-02-28
EP3282258A1 (en) 2018-02-14
MX2015002061A (es) 2015-06-05
US10041957B2 (en) 2018-08-07
US20180335437A1 (en) 2018-11-22
MX358541B (es) 2018-08-24
PL2885641T3 (pl) 2018-04-30
CN104737023B (zh) 2017-07-28
EP2885641A4 (en) 2016-03-23
SG11201501200XA (en) 2015-04-29
JP6757757B2 (ja) 2020-09-23

Similar Documents

Publication Publication Date Title
DK2885641T3 (da) Fremgangsmådeer til forudsigelse af risiko for udvikling af hypertension
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
WO2013066369A3 (en) Methods for detecting graft-versus-host disease
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
EA201590027A1 (ru) Способы детекции заболеваний или состояний
WO2012115820A3 (en) Biomarker panels, diagnostic methods and test kits for ovarian cancer
WO2012166899A3 (en) Biomarkers for predicting and assessing responsiveness to lenvatinib compounds
WO2013087887A3 (en) Biomarkers and parameters for preeclampsia
EA201301180A1 (ru) Основанная на bcma стратификация и терапия пациентов, страдающих множественной миеломой
MX2020010947A (es) Metodos de tratamiento de enfermedad de alzheimer.
NZ606725A (en) Methods for predicting anti-cancer response
WO2015176066A3 (en) Lpa-associated protein and rna expression
WO2013096822A3 (en) Test device for optical and electrochemical assays
EA201890925A2 (ru) Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
BR112012030587A2 (pt) métodos para diagnóstico de câncer pancreático, para identificar se um indivíduo precisa ou não de uma terapia contra câncer pancreático e para determinar se uma terapia contra câncer pancreático obtém sucesso, dispositivo para diagnóstico de câncer pancreático e uso de pelo menos um biomarcador
BR112013008602A2 (pt) dispositivo imunocromatográfico, método para a determinação de um carreador gênico, método para o diagnóstico, dispositivo para ensaio imunológico, método para a detecção e determinação da presença de uma proteína e kit
EA201590024A1 (ru) Способы определения заболеваний или состояний с применением циркулирующих болезненных клеток
EA201492284A1 (ru) Применение маркеров в диагностике и лечении рака предстательной железы
MX357429B (es) Predictores para el tratamiento del cáncer.
WO2013028807A3 (en) Renal cell carcinoma biomarkers and uses thereof
WO2014187884A3 (en) Mirnas as non-invasive biomarkers for heart failure
MX2016002529A (es) Marcadores de riesgo para cardiovasculopatias en pacientes con nefropatia cronica.
EA201171239A1 (ru) Способ детекции типа паппиломавируса человека (hpv)
MX2013002652A (es) Metodos y equipos para la deteccion de una infeccion en sujetos con bajos niveles de anticuerpos especificos.
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia